Increased Scrutiny of U.S. Clinical Trials in China

A bipartisan group of lawmakers called on the Biden administration to increase scrutiny of U.S. clinical trials conducted in China due to concerns about intellectual property theft and forced participation of Uyghurs. Reuters is the world's largest multimedia news provider.